• NeOnc reports that Phase 2a trial of NEO100 intranasal perillyl alcohol in patients with brain tumors met its primary endpoint

  NeOnc Technologies announced that the Phase 2a NEO100-01 study of NEO100 intranasal perillyl alcohol in patients with Grade 3 and Grade 4 IDH1-mutant gliomas met its primary endpoint, achieving a 48.9% 6-month progression-free survival rate.… [Read more . . .]

• Scienture launches Rezenopy naloxone nasal spray in the US

  Scienture Holdings announced that the company has launched Rezenopy naloxone nasal spray in the US. Scienture acquired the US rights to Rezenopy from Summit Biosciences, a subsidiary of Kindeva Drug Delivery, in 2025. The FDA approved Summit’s… [Read more . . .]

• Zydus launches Revahale revefenacin inhalation solution for the treatment of COPD in India

  Zydus Lifesciences has announced the launch of its Revahale revefenacin inhalation solution in India. The company highlights that Revahale is the country’s first once-daily nubulized LAMA for the treatment of COPD, noting that the inhalation… [Read more . . .]

• ReCode Therapeutics names Heather Clark as its new CEO

  ReCode Therapeutics, which is developing inhaled mRNA therapies, announced that Heather Clark will succeed Shehnaaz Suliman as the company’s CEO, with Suliman becoming executive chair of the board. Clark joined ReCode in 2022 and has… [Read more . . .]

• Harrow acquires Tyrvaya varenicline nasal spray for the treatment of dry eye disease

  US-based opthalmic pharmaceuticals company Harrow announced that it will pay Viatris $30 million up front and up to $70 million in milestone payments to acquire Tyrvaya varenicline nasal spray. Tyrvaya was approved by the FDA… [Read more . . .]

• Savara gets 2 new patents covering Molbreevi molgramostim inhalation solution

• MannKind says that the Phase 1b INFLO-1 trial of its nintedanib DPI met its primary endpoint

• Nasus Pharma names Brendan O’Grady as its new CEO

• Chiesi returns the rights to seralutinib DPI for pulmonary hypertension to Gossamer

• Revagenix initiates Phase 1 trial of Rev-56 inhaled antibiotic for NCFB

More news . . .